Epidemiological Study of Lung Cancer in Iran: A Systematic Review
Abstract
Background: There is no comprehensive study addressing all the epidemiological aspects of Lung cancer (LC) in Iran, therefore this systematic review investigated the epidemiological aspects of lung cancer in Iran.
Methods: The search was performed until the Aug. 2020 on the in international databases based on PRISMA protocol by Pulmonary Neoplasms, Lung Neoplasm, Neoplasm, Lung, Lung Cancer, Cancer, Pulmonary Cancer, Cancer, Pulmonary, Cancers, Cancer of the Lung, Iran, incidence, death, risk factors keywords and different combinations of them. Articles that evaluated epidemiological aspects of lung cancer were included in the analysis.
Results: Of 1420 articles, 82 cases were entered the analysis. Based on studies, in Iran, lung cancer has been the most common cancer and its prevalence is increasing. Squamous cell carcinoma and adenocarcinoma is the most common type of lung cancer in men and women, respectively. Cigarette smoking, human papilloma virus (HPV) infection, mustard gas, occupational risk factors and genetic factors considered as the major reported risk factors for lung cancer and vegetarian diet as a protective factor.
Conclusion: In according to the increasing trend of incidence and mortality of lung cancer in Iran, elimination of the major risk factors can decrease this issue and national comprehensive planning should be considered in health promotion plans.
1. Siegel RL, Miller KD, Jemal A (2019). Can-cer statistics. CA Cancer J Clin, 69(1): 7-34.
2. Wong MCS, Lao XQ, Ho K-F, et al (2017). Incidence and mortality of lung cancer: global trends and association with socio-economic status. Sci Rep, 7(1): 14300.
3. Roshandel G, Ghanbari-Motlagh A, Par-tovipour E, et al (2019). Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Regis-try. Cancer Epidemiol, 61: 50-8.
4. Sadeghi-Gandomani H, Asgari-Tarazoj A, Ghoncheh M, et al (2017). Lung cancer in the world: the incidence, mortality rate and risk factors. WCRJ, 4: e911.
5. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339: b2535.
6. Sadjadi A, Nouraie M, Mohagheghi MA, et al (2005). Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev, 6(3): 359-63.
7. Almasi Z, Mohammadian-Hafshejani A, Salehiniya H (2016). Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. J BUON, 21(4):994-1004.
8. Bab S, Abdifard E, Moradi Y, et al (2016). Lung cancer incidence trends in Iran and in six geographical regions of the country (2000 - 2005). Shiraz E Medical Journal, 17(6): e38237.
9. Enayatrad M, Mirzaei M, Salehiniya H, et al (2016). Trends in Incidence of Common Cancers in Iran. Asian Pac J Cancer Prev, 17(S3):39-42.
10. Mohagheghi MA, Mousavi-Jarrahi Y, Mo-savi-Jarrahi A (2011). Cost of care for lung cancer in the first year after diagno-sis in Iran. Asian Pac J Cancer Prev, 12(4):1013-5.
11. Sadjadi A, Malekzadeh R, Derakhshan M, et al (2003). Cancer occurrence in Ardabil: Results of a population-based Cancer Registry from Iran. Int J Cancer, 107: 113-8.
12. Sajadi A, Zahedi MJ, Moghadam SD, et al (2007). The First Population-Based Can-cer Survey in Kerman Province of Iran. Iran J Public Health, 36(4): 26-34.
13. Babaei M, Jaafarzadeh H, Sadjadi AR, et al (2009). Cancer Incidence and Mortality in Ardabil: Report of an Ongoing Popula-tion-Based Cancer Registry in Iran, 2004-2006. Iran J Public Health, 38(4): 25-35.
14. Roshandel G, Sadjadi A, Aarabi M, et al (2012). Cancer incidence in golestan province: report of an ongoing popula-tion-based cancer registry in Iran between 2004 and 2008. Arch Iran Med, 15(4): 196-200.
15. Amoori N, Mirzaei M, Cheraghi M (2014). Incidence of Cancers in Kuzestan Prov-ince of Iran: Trend from 2004 to 2008. Asian Pac J Cancer Prev, 15(19): 8345-9.
16. Shahesmaeili A, Afshar R.M, Sadeghi A, et al (2018). Cancer incidence in Kerman Province, Southeast of Iran: Report of an ongoing population-based cancer regis-try, 2014. Asian Pac J Cancer Prev, 19(6): 1533-41.
17. Somi Mh, Mousavi Sm, Rezaeifar P, et al (2009). Cancer incidence among the el-derly population in the northwest of Iran: a population based study. Int J Cancer, 2(3): 117-26.
18. Mezginejad F, Haghighi F, Behravan M, et al (2016). Cancer Types in Pathological Samples Referred to Educational Hospi-tals in Birjand During the Past Three Years (2011 - 2013). Int J Cancer Manag, 9(5): e4075.
19. Kolahi AA, Mosavi-Jarrahi A (2007). Inci-dence of occupational lung cancer in Tehran-Iran. Journal of Thoracic Oncology, 2(8):S343-S4.
20. Mohagheghi Sma, Mousavi Jarahi Sar, Ma-lekzadeh R, et al (2009). Cancer incidence in Tehran metropolis: the first report from the tehran population-based cancer registry, 1998 – 2001. Arch Iran Med, 12(1): 15-23.
21. Masoompour SM, Yarmohammadi H, Re-zaianzadeh A, et al (2011). Cancer inci-dence in southern Iran, 1998–2002: Re-sults of population-based cancer registry. Cancer Epidemiol, 35(5):e42-7.
22. Karami K, Cheraghi M, Amori N, et al (2014). Common Cancers in Khuzestan Province, South West of Iran, during 2005-2011. Asian Pac J Cancer Prev, 15(21):9475-8.
23. Rohani-Rasaf M, Rohani-Rasaf MR, Hash-emi Nazari SS, et al (2017). Cancer Inci-dence Rate in the Elderly Inhabitants of Tehran: Is there really any Cluster? Int J Cancer Manag, 10(7):e5753.
24. Keyghobadi N, Rafiemanesh H, Moham-madian-Hafshejani A, et al (2015). Epi-demiology and trend of cancers in the province of Kerman: southeast of Iran. Asian Pac J Cancer Prev, 16(4): 1409-13.
25. Rahimi Z, Kasraei R, Najafi F, et al (2015). Cancer notification at a referral hospital of Kermanshah, Western Iran (2006-2009). Asian Pac J Cancer Prev, 16(1): 133-7.
26. Bozorgi F, Hedayatizadeh-Omran A, Aliza-deh-Navaei R, et al (2017). Causes of Death of Cancer Patients in a Referral Hospital in Northern Iran between 2013 and 2016. WCRJ, 4 (3): e909.
27. Vardanjani HM, Zeinali M, Radmerikhi S, et al (2017). Lung Cancer Prevalence in Iran by Histologic Subtypes. Adv Biomed Res, 6:111.
28. Tolou Ghamari Z (2018). Prevalence of lung cancer in Isfahan Province, Iran. 2018. J Egypt Natl Canc Inst, 30(2): 57-9.
29. Modirian M, Rahimzadeh S, Cheraghi Z, et al (2015). Burden of Cancers in Iran from 1990 to 2010: findings from the Global Burden of Disease study 2010. Arch Iran Med, 18(10): 629-37.
30. Rajai N, Ghanbari A, Yoosefi M, et al (2020). National and subnational trends in incidence and mortality of lung cancer in Iran from 1990 to 2016. Asia Pac J Clin Oncol, 16(3): 129-36.
31. Ghasemi S, Mahaki B, Dreassi E, et al (2020). Spatial Variation in Lung Cancer Mortality and Related Men-Women Dis-parities in Iran from 2011 to 2014. Cancer Manag Res, 12: 4615-24.
32. Global Cancer Observatory (2021). Iran-islamic-republic-of-fact-sheets: The Global Cancer Observatory. International Agency for Research on Cancer, Lyon, France. Available from: https://gco.iarc.fr/today/data/factsheets/populations/364-iran-islamic-republic-of-fact-sheets.pdf.
33. Almasi Z, Salehiniya H, Amoori N, et al (2016). Epidemiology Characteristics and Trends of Lung Cancer Incidence in Iran. Asian Pac J Cancer Prev, 17(2): 557-62.
34. Khazaei S, Mansori K, Soheylizad M, et al (2017). Epidemiology of lung cancer in Iran: Sex difference and geographical dis-tribution. Middle East Journal of Cancer, 8: 223-8.
35. Motovali-bashi M, Taghvaei S, Hemati S (2012). The Association between Gelati-nase B and Lung Cancer in Smokers and Non-Smokers. Journal of Isfahan Medical School, 30:1393-402.
36. Ghobadi H, Sharghi A, Sadat-Kermani J (2013). Epidemiology and Risk Factors for Lung Cancer in Ardabil, Iran. JAr-UMS, 13(2): 220-8.
37. Abbasi M, Moradi F, Esna-Ashari F, et al (2019). Epidemiological and Pathological Study of Lung Cancer in Patients Re-ferred to Ekbatan and Shahid Beheshti Hospitals in Hamadan during 2001 - 2016. Avicenna Journal of Clinical Medicine, 25(4): 236-43.
38. Adnan K, Esfahani-Monfared Z, Sei S, et al (2016). Clinicopathological Characteristics of Iranian Patients with Lung Cancer: a Single Institute Experience. Asian Pac J Cancer Prev, 17(8): 3817-22.
39. Shahbazi-Gahrouei D, Danesh A (2004). Investigation of cancers incidence rele-vant to radiation in Chaharmahal and Bakhtiari province during five years (1998-2002). J Shahrekord Univ Med Sci, 6(1):7-13.
40. Adham D, Asl E, Abbasgholizadeh N, et al (2019). Spatial Analysis and Epidemiology of Lung Cancer in the Northwest of Iran. P J M H S, (12): 20181851.
41. Hajmanoochehri F, Mohammadi N, Zohal MA, et al (2014). Epidemiological and clinicopathological characteristics of lung cancer in a teaching hospital in Iran. Asian Pac J Cancer Prev, 15(6):2495-500.
42. Salari A, Taghipour S, Moghimi M, et al (2012). Evaluation of frequency of clinical and pathological findings in lung diseases in shahid Sadoughi University of medical sciences of yazd, during 2001-2006. Irani-an Journal of Surgery, 20(1): 27-33.
43. Abedi S, Janbabaee G, Moosazadeh M, et al (2017). Epidemiology of Lung Cancer Patients Attending Tooba Clinic and Imam Khomeini Hospital, Sari, Iran 2010-2014. J Mazandaran Univ Med Sci, 27(151): 86-93.
44. Akbarzadeh Ba, Esmaeili M, Kimiafar K (2009). Medical information management and assessment of direct costs of treat-ment of lung cancer. Health Information Management, 5(2):151-8.
45. Hosseini M, Naghan PA, Karimi S, et al (2009). Environmental risk factors for lung cancer in Iran: a case–control study. Int J Epidemiol, 38(4): 989-96.
46. Ghobadi M, Farrokhi MR, Nakhaee N, et al (2017). Estimation of the Cost of Smok-ing-Attributable Diseases (Five Selected Diseases): A Case in Kerman City, Iran, 2014. Addict Health, 9(4): 190-8.
47. Hosseini M, Naghan PA, Jafari AM, et al (2014). Nutrition and lung cancer: a case control study in Iran. BMC Cancer, 14: 860.
48. Najafi F, Moradinazar M, Barati M JT, et al (2016). Correlation between risk factors for non-communicable diseases and common cancers in Iran: Ecological study. International Business Management, 10(15):3015-9.
49. Masjedi MR, Naghan PA, Taslimi S, et al (2013). Opium Could Be Considered an Independent Risk Factor for Lung Can-cer: A Case-Control Study. Respiration, 85(2):112-8.
50. Akbari AB, Rezaei S, Arab M, et al (2016). Effects of Smoking on Cost of Hospital-ization and Length of Stay among Pa-tients with Lung Cancer in Iran: a Hospi-tal-Based Study. Asian Pac J Cancer Prev, 17(9):4421-6.
51. Zafarghandi MR, Soroush MR, Mahmoodi M, et al (2013). Incidence of cancer in Iranian sulfur mustard exposed veterans: a long-term follow-up cohort study. Can-cer Causes Control, 24(1): 99-105.
52. Nadji SA, Mahmoodi M, Ziaee AA, et al (2007). An increased lung cancer risk as-sociated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. Lung Cancer, 56(2): 145-51.
53. Hosseini-khalili A, Haines DD, Modirian E, et al (2009). Mustard gas exposure and carcinogenesis of lung. Mutat Res, 678(1): 1-6.
54. Alberg AJ, Yung RC, Strickland PT, J. N (2002). Respiratory cancer and exposure to arsenic, chromium, nickel, and polycy-clic aromatic hydrocarbons. Clinics in Occupational and Environmental Medi-cine. Bloomberg School of Public Health, 2(4): 779-801.
55. Rashidi M, Rameshat MH, R. R (2014). Ge-ographic Health and Human Health; Us-ing Space Technology and Remote Sens-ing in Monitoring Soil Pollution by Arse-nic and the Related Lung Cancer in Isfa-han, Iran: A Case Study. Journal of Isfahan Medical Sciences, 32(287): 784-90.
56. Karimzadeh L, Koohdani F, Siassi F, et al (2012). Relation between nitrate and ni-trite food habits with lung cancer. J Exp Ther Oncol, 10(2):107-12.
57. Hadei M, Hashemi Nazari SS, Yarahmadi M, et al (2017). Estimation of Gender-Specific Lung Cancer Deaths due to Ex-posure to PM2.5 in 10 Cities of Iran dur-ing 2013 - 2016: A Modeling Approach. Int J Cancer Manag, 10(8):e10235.
58. Mobasheri MR, A. H (2014). Using Satellite Images for Determination of Critical Points in Polluted Cities and their Rela-tion to Lung Cancer Affection. Hakim Health Systems Research Journal, 17(2):151-8.
59. Razmkhah M, Doroudchi M, Ghayumi SM, et al (2005). Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer, 49(3):311-5.
60. Mosavi-Jarrahi A, Mohagheghi M, Kalagh-chi B, et al (2009). Estimating the inci-dence of lung cancer attributable to occu-pational exposure in Iran. Popul Health Metr, 7:7.
61. Karimzadeh L, Koohdani F, Siassi F, et al (2011). A case control study on the lung cancer risk factors in north of Iran. J Exp Ther Oncol, 9(2): 153-8.
62. Mahaki B, Mehrabi Y, Kavousi A, et al (2011). Multivariate disease mapping of seven prevalent cancers in Iran using a shared component model. Asian Pac J Cancer Prev, 12(9): 2353-8.
63. Safari A, Reazai M, Tangestaninejad A, et al (2016). Opium consumption: A potential risk factor for lung cancer and pulmonary tuberculosis. Indian J Cancer, 53(4): 587-9.
64. Dehghani M, Samani Z, Abidi H, et al (2018). Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransfer-ase 1 Gene Promoter with Susceptibility to Lung Cancer. Int J Genomics, 2018:4863757.
65. Motovali-Bashi M, Biglari M, Hojati Z, et al (2012). Role of CYP1A1 MspI polymor-phism in CYP1A1 gene with susceptibil-ity to lung cancer in Iranian patients. J Res Med Sci, 17(5):1.
66. Keeley BR, Islami F, Pourshams A, et al (2014). Prediagnostic serum levels of in-flammatory biomarkers are correlated with future development of lung and esophageal cancer. Cancer Sci, 105(9):1205-11.
67. Nikseresht M, Shahverdi M, Dehghani M, et al (2018). Association of single nucleotide autophagy-related protein 5 gene poly-morphism rs2245214 with susceptibility to non-small cell lung cancer. J Cell Bio-chem, 120(2):1924-31.
68. Adibhesami G, Shahsavari GR, Amiri A, et al (2018). Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) Polymor-phisms and Lung Cancer Risk among a Select Group of Iranian People. Asian Pac J Cancer Prev, 19(10): 2921-7.
69. Rahmati A, Shakeri R, Khademi H, et al (2017). Mortality from respiratory diseas-es associated with opium use: a popula-tion-based cohort study. Thorax, 72(11): 1028-34.
70. Eydian Z, Asna'ashari AM, Behravan J, et al (2016). Association of P53 codon 72 pol-ymorphism and lung cancer in an ethnic Iranian population. Cell Mol Biol (Noisy-le-grand), 62(9):34-8.
71. Motovali-Bashi M, Rezaei H, Dehghanian F, et al (2014). Association between XPD (Lys751G1n) Polymorphism and Lung Cancer Risk: A Population-Based Study in Iran. Cell J, 16(3): 309-14.
72. Rikhtegar S, Hesampour A (2018). Investiga-tion of KRAS and NRAS expression lev-els in lung cancer patients compared to normal patients. Yafte, 20(3): 19-27.
73. Ahmadi M, Moshtaghioun SM, Falahati A (2018). Association of the CHRNA3 rs1051730 single nucleotide polymor-phism with lung cancer risk in Iranian pa-tients. JSSU, 26(7): 599-606.
74. Chitsaz M, Hesampour A (2018). Investigat-ing the Expression of EGFR and FGFR4 Genes in Patients with Lung Cancer. JBUMS, 20(4): 17-23.
75. Amini F, Motovalli Bashi M, Hemmati S (2018). Study of egfr gene in relationship between polymorphism and mir-214 binding site in lung cancer. Pejouhesh dar Pezeshki (Research in Medicine), 41(4): 268-274.
76. Motovali-bashi M, Taghvaei S, Hemati S (2012). The association between the C(-1562)t polymorphism of type IV colla-genase gene and reduced age of onset of lung cancer. Journal of Isfahan Medical School, 30(203): 1-9
77. Motovali-Bashi M, Bordbar M, Rezaei H (2012). Study of association between T/C single nucleotide polymorphism in CYP1A1 gene and cancer initiation and smoking status in lung cancer patients. Pejouhesh dar Pezeshki (Research in Medicine), 36(3): 151-6.
78. Motovali-Bashi M, Hojati Z (2013). Investi-gation of correlation between -765G/C polymorphism of cyclooxygenase 2 genes and lung cancer in Isfahan popula-tion. Pejouhesh dar Pezeshki (Research in Medi-cine), 37(1): 47-54.
79. Ghayyoumi M, Mansouri M (2015). Deter-mination of Serum level of Triose Phos-phate Isomerase in lung Cancer Patients. Armaghane Danesh, 19(11): 948-54.
80. Hamedi F, Tahmaseb M, A G (2016). Prog-nostic Importance of Polymorphisms in DNA-Repair Gene (XRCC1 Arg399Gln) in Patients with Lung Cancer in Fars Province, Iran. Journal of Isfahan Medical School, 34(403): 1244-50.
81. Keshvary Ravan H, Kouhkan F, Sazgar H (2017). Single Nucleotide Polymorphisms of MMP2 Gene Promoter on the Risk of Development and Metastasis of lung Cancer. Armaghane Danesh, 22(1): 104-17.
82. Sazgar H (2017). Evaluation of correlation between -1562 C/T in promoter single nucleotide polymorphisms of MMP-9 gene and lung cancer initiationand metas-tasis risk. Pars of Jahrom University of Medical Sciences, 15(2): 9-16.
83. Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, et al (2015). The incidence and mortality of lung cancer and their re-lationship to development in Asia. Transl Lung Cancer Res, 4(6): 763-74.
84. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer inci-dence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19(8):1893-907.
85. Bogos K, Kiss Z, Gálffy G, et al (2019). Re-vising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemi-ology Review from Hungary. Front Oncol, 9:1051.
86. de Groot P, Munden RF (2012). Lung can-cer epidemiology, risk factors, and pre-vention. Radiol Clin North Am, 50(5): 863-76.
87. Jazieh AR, AlGhamdi M, AlGhanem S, et al (2018). Saudi lung cancer prevention and screening guidelines. Ann Thorac Med, 13(4):198-204.
2. Wong MCS, Lao XQ, Ho K-F, et al (2017). Incidence and mortality of lung cancer: global trends and association with socio-economic status. Sci Rep, 7(1): 14300.
3. Roshandel G, Ghanbari-Motlagh A, Par-tovipour E, et al (2019). Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Regis-try. Cancer Epidemiol, 61: 50-8.
4. Sadeghi-Gandomani H, Asgari-Tarazoj A, Ghoncheh M, et al (2017). Lung cancer in the world: the incidence, mortality rate and risk factors. WCRJ, 4: e911.
5. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339: b2535.
6. Sadjadi A, Nouraie M, Mohagheghi MA, et al (2005). Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev, 6(3): 359-63.
7. Almasi Z, Mohammadian-Hafshejani A, Salehiniya H (2016). Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. J BUON, 21(4):994-1004.
8. Bab S, Abdifard E, Moradi Y, et al (2016). Lung cancer incidence trends in Iran and in six geographical regions of the country (2000 - 2005). Shiraz E Medical Journal, 17(6): e38237.
9. Enayatrad M, Mirzaei M, Salehiniya H, et al (2016). Trends in Incidence of Common Cancers in Iran. Asian Pac J Cancer Prev, 17(S3):39-42.
10. Mohagheghi MA, Mousavi-Jarrahi Y, Mo-savi-Jarrahi A (2011). Cost of care for lung cancer in the first year after diagno-sis in Iran. Asian Pac J Cancer Prev, 12(4):1013-5.
11. Sadjadi A, Malekzadeh R, Derakhshan M, et al (2003). Cancer occurrence in Ardabil: Results of a population-based Cancer Registry from Iran. Int J Cancer, 107: 113-8.
12. Sajadi A, Zahedi MJ, Moghadam SD, et al (2007). The First Population-Based Can-cer Survey in Kerman Province of Iran. Iran J Public Health, 36(4): 26-34.
13. Babaei M, Jaafarzadeh H, Sadjadi AR, et al (2009). Cancer Incidence and Mortality in Ardabil: Report of an Ongoing Popula-tion-Based Cancer Registry in Iran, 2004-2006. Iran J Public Health, 38(4): 25-35.
14. Roshandel G, Sadjadi A, Aarabi M, et al (2012). Cancer incidence in golestan province: report of an ongoing popula-tion-based cancer registry in Iran between 2004 and 2008. Arch Iran Med, 15(4): 196-200.
15. Amoori N, Mirzaei M, Cheraghi M (2014). Incidence of Cancers in Kuzestan Prov-ince of Iran: Trend from 2004 to 2008. Asian Pac J Cancer Prev, 15(19): 8345-9.
16. Shahesmaeili A, Afshar R.M, Sadeghi A, et al (2018). Cancer incidence in Kerman Province, Southeast of Iran: Report of an ongoing population-based cancer regis-try, 2014. Asian Pac J Cancer Prev, 19(6): 1533-41.
17. Somi Mh, Mousavi Sm, Rezaeifar P, et al (2009). Cancer incidence among the el-derly population in the northwest of Iran: a population based study. Int J Cancer, 2(3): 117-26.
18. Mezginejad F, Haghighi F, Behravan M, et al (2016). Cancer Types in Pathological Samples Referred to Educational Hospi-tals in Birjand During the Past Three Years (2011 - 2013). Int J Cancer Manag, 9(5): e4075.
19. Kolahi AA, Mosavi-Jarrahi A (2007). Inci-dence of occupational lung cancer in Tehran-Iran. Journal of Thoracic Oncology, 2(8):S343-S4.
20. Mohagheghi Sma, Mousavi Jarahi Sar, Ma-lekzadeh R, et al (2009). Cancer incidence in Tehran metropolis: the first report from the tehran population-based cancer registry, 1998 – 2001. Arch Iran Med, 12(1): 15-23.
21. Masoompour SM, Yarmohammadi H, Re-zaianzadeh A, et al (2011). Cancer inci-dence in southern Iran, 1998–2002: Re-sults of population-based cancer registry. Cancer Epidemiol, 35(5):e42-7.
22. Karami K, Cheraghi M, Amori N, et al (2014). Common Cancers in Khuzestan Province, South West of Iran, during 2005-2011. Asian Pac J Cancer Prev, 15(21):9475-8.
23. Rohani-Rasaf M, Rohani-Rasaf MR, Hash-emi Nazari SS, et al (2017). Cancer Inci-dence Rate in the Elderly Inhabitants of Tehran: Is there really any Cluster? Int J Cancer Manag, 10(7):e5753.
24. Keyghobadi N, Rafiemanesh H, Moham-madian-Hafshejani A, et al (2015). Epi-demiology and trend of cancers in the province of Kerman: southeast of Iran. Asian Pac J Cancer Prev, 16(4): 1409-13.
25. Rahimi Z, Kasraei R, Najafi F, et al (2015). Cancer notification at a referral hospital of Kermanshah, Western Iran (2006-2009). Asian Pac J Cancer Prev, 16(1): 133-7.
26. Bozorgi F, Hedayatizadeh-Omran A, Aliza-deh-Navaei R, et al (2017). Causes of Death of Cancer Patients in a Referral Hospital in Northern Iran between 2013 and 2016. WCRJ, 4 (3): e909.
27. Vardanjani HM, Zeinali M, Radmerikhi S, et al (2017). Lung Cancer Prevalence in Iran by Histologic Subtypes. Adv Biomed Res, 6:111.
28. Tolou Ghamari Z (2018). Prevalence of lung cancer in Isfahan Province, Iran. 2018. J Egypt Natl Canc Inst, 30(2): 57-9.
29. Modirian M, Rahimzadeh S, Cheraghi Z, et al (2015). Burden of Cancers in Iran from 1990 to 2010: findings from the Global Burden of Disease study 2010. Arch Iran Med, 18(10): 629-37.
30. Rajai N, Ghanbari A, Yoosefi M, et al (2020). National and subnational trends in incidence and mortality of lung cancer in Iran from 1990 to 2016. Asia Pac J Clin Oncol, 16(3): 129-36.
31. Ghasemi S, Mahaki B, Dreassi E, et al (2020). Spatial Variation in Lung Cancer Mortality and Related Men-Women Dis-parities in Iran from 2011 to 2014. Cancer Manag Res, 12: 4615-24.
32. Global Cancer Observatory (2021). Iran-islamic-republic-of-fact-sheets: The Global Cancer Observatory. International Agency for Research on Cancer, Lyon, France. Available from: https://gco.iarc.fr/today/data/factsheets/populations/364-iran-islamic-republic-of-fact-sheets.pdf.
33. Almasi Z, Salehiniya H, Amoori N, et al (2016). Epidemiology Characteristics and Trends of Lung Cancer Incidence in Iran. Asian Pac J Cancer Prev, 17(2): 557-62.
34. Khazaei S, Mansori K, Soheylizad M, et al (2017). Epidemiology of lung cancer in Iran: Sex difference and geographical dis-tribution. Middle East Journal of Cancer, 8: 223-8.
35. Motovali-bashi M, Taghvaei S, Hemati S (2012). The Association between Gelati-nase B and Lung Cancer in Smokers and Non-Smokers. Journal of Isfahan Medical School, 30:1393-402.
36. Ghobadi H, Sharghi A, Sadat-Kermani J (2013). Epidemiology and Risk Factors for Lung Cancer in Ardabil, Iran. JAr-UMS, 13(2): 220-8.
37. Abbasi M, Moradi F, Esna-Ashari F, et al (2019). Epidemiological and Pathological Study of Lung Cancer in Patients Re-ferred to Ekbatan and Shahid Beheshti Hospitals in Hamadan during 2001 - 2016. Avicenna Journal of Clinical Medicine, 25(4): 236-43.
38. Adnan K, Esfahani-Monfared Z, Sei S, et al (2016). Clinicopathological Characteristics of Iranian Patients with Lung Cancer: a Single Institute Experience. Asian Pac J Cancer Prev, 17(8): 3817-22.
39. Shahbazi-Gahrouei D, Danesh A (2004). Investigation of cancers incidence rele-vant to radiation in Chaharmahal and Bakhtiari province during five years (1998-2002). J Shahrekord Univ Med Sci, 6(1):7-13.
40. Adham D, Asl E, Abbasgholizadeh N, et al (2019). Spatial Analysis and Epidemiology of Lung Cancer in the Northwest of Iran. P J M H S, (12): 20181851.
41. Hajmanoochehri F, Mohammadi N, Zohal MA, et al (2014). Epidemiological and clinicopathological characteristics of lung cancer in a teaching hospital in Iran. Asian Pac J Cancer Prev, 15(6):2495-500.
42. Salari A, Taghipour S, Moghimi M, et al (2012). Evaluation of frequency of clinical and pathological findings in lung diseases in shahid Sadoughi University of medical sciences of yazd, during 2001-2006. Irani-an Journal of Surgery, 20(1): 27-33.
43. Abedi S, Janbabaee G, Moosazadeh M, et al (2017). Epidemiology of Lung Cancer Patients Attending Tooba Clinic and Imam Khomeini Hospital, Sari, Iran 2010-2014. J Mazandaran Univ Med Sci, 27(151): 86-93.
44. Akbarzadeh Ba, Esmaeili M, Kimiafar K (2009). Medical information management and assessment of direct costs of treat-ment of lung cancer. Health Information Management, 5(2):151-8.
45. Hosseini M, Naghan PA, Karimi S, et al (2009). Environmental risk factors for lung cancer in Iran: a case–control study. Int J Epidemiol, 38(4): 989-96.
46. Ghobadi M, Farrokhi MR, Nakhaee N, et al (2017). Estimation of the Cost of Smok-ing-Attributable Diseases (Five Selected Diseases): A Case in Kerman City, Iran, 2014. Addict Health, 9(4): 190-8.
47. Hosseini M, Naghan PA, Jafari AM, et al (2014). Nutrition and lung cancer: a case control study in Iran. BMC Cancer, 14: 860.
48. Najafi F, Moradinazar M, Barati M JT, et al (2016). Correlation between risk factors for non-communicable diseases and common cancers in Iran: Ecological study. International Business Management, 10(15):3015-9.
49. Masjedi MR, Naghan PA, Taslimi S, et al (2013). Opium Could Be Considered an Independent Risk Factor for Lung Can-cer: A Case-Control Study. Respiration, 85(2):112-8.
50. Akbari AB, Rezaei S, Arab M, et al (2016). Effects of Smoking on Cost of Hospital-ization and Length of Stay among Pa-tients with Lung Cancer in Iran: a Hospi-tal-Based Study. Asian Pac J Cancer Prev, 17(9):4421-6.
51. Zafarghandi MR, Soroush MR, Mahmoodi M, et al (2013). Incidence of cancer in Iranian sulfur mustard exposed veterans: a long-term follow-up cohort study. Can-cer Causes Control, 24(1): 99-105.
52. Nadji SA, Mahmoodi M, Ziaee AA, et al (2007). An increased lung cancer risk as-sociated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. Lung Cancer, 56(2): 145-51.
53. Hosseini-khalili A, Haines DD, Modirian E, et al (2009). Mustard gas exposure and carcinogenesis of lung. Mutat Res, 678(1): 1-6.
54. Alberg AJ, Yung RC, Strickland PT, J. N (2002). Respiratory cancer and exposure to arsenic, chromium, nickel, and polycy-clic aromatic hydrocarbons. Clinics in Occupational and Environmental Medi-cine. Bloomberg School of Public Health, 2(4): 779-801.
55. Rashidi M, Rameshat MH, R. R (2014). Ge-ographic Health and Human Health; Us-ing Space Technology and Remote Sens-ing in Monitoring Soil Pollution by Arse-nic and the Related Lung Cancer in Isfa-han, Iran: A Case Study. Journal of Isfahan Medical Sciences, 32(287): 784-90.
56. Karimzadeh L, Koohdani F, Siassi F, et al (2012). Relation between nitrate and ni-trite food habits with lung cancer. J Exp Ther Oncol, 10(2):107-12.
57. Hadei M, Hashemi Nazari SS, Yarahmadi M, et al (2017). Estimation of Gender-Specific Lung Cancer Deaths due to Ex-posure to PM2.5 in 10 Cities of Iran dur-ing 2013 - 2016: A Modeling Approach. Int J Cancer Manag, 10(8):e10235.
58. Mobasheri MR, A. H (2014). Using Satellite Images for Determination of Critical Points in Polluted Cities and their Rela-tion to Lung Cancer Affection. Hakim Health Systems Research Journal, 17(2):151-8.
59. Razmkhah M, Doroudchi M, Ghayumi SM, et al (2005). Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer, 49(3):311-5.
60. Mosavi-Jarrahi A, Mohagheghi M, Kalagh-chi B, et al (2009). Estimating the inci-dence of lung cancer attributable to occu-pational exposure in Iran. Popul Health Metr, 7:7.
61. Karimzadeh L, Koohdani F, Siassi F, et al (2011). A case control study on the lung cancer risk factors in north of Iran. J Exp Ther Oncol, 9(2): 153-8.
62. Mahaki B, Mehrabi Y, Kavousi A, et al (2011). Multivariate disease mapping of seven prevalent cancers in Iran using a shared component model. Asian Pac J Cancer Prev, 12(9): 2353-8.
63. Safari A, Reazai M, Tangestaninejad A, et al (2016). Opium consumption: A potential risk factor for lung cancer and pulmonary tuberculosis. Indian J Cancer, 53(4): 587-9.
64. Dehghani M, Samani Z, Abidi H, et al (2018). Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransfer-ase 1 Gene Promoter with Susceptibility to Lung Cancer. Int J Genomics, 2018:4863757.
65. Motovali-Bashi M, Biglari M, Hojati Z, et al (2012). Role of CYP1A1 MspI polymor-phism in CYP1A1 gene with susceptibil-ity to lung cancer in Iranian patients. J Res Med Sci, 17(5):1.
66. Keeley BR, Islami F, Pourshams A, et al (2014). Prediagnostic serum levels of in-flammatory biomarkers are correlated with future development of lung and esophageal cancer. Cancer Sci, 105(9):1205-11.
67. Nikseresht M, Shahverdi M, Dehghani M, et al (2018). Association of single nucleotide autophagy-related protein 5 gene poly-morphism rs2245214 with susceptibility to non-small cell lung cancer. J Cell Bio-chem, 120(2):1924-31.
68. Adibhesami G, Shahsavari GR, Amiri A, et al (2018). Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) Polymor-phisms and Lung Cancer Risk among a Select Group of Iranian People. Asian Pac J Cancer Prev, 19(10): 2921-7.
69. Rahmati A, Shakeri R, Khademi H, et al (2017). Mortality from respiratory diseas-es associated with opium use: a popula-tion-based cohort study. Thorax, 72(11): 1028-34.
70. Eydian Z, Asna'ashari AM, Behravan J, et al (2016). Association of P53 codon 72 pol-ymorphism and lung cancer in an ethnic Iranian population. Cell Mol Biol (Noisy-le-grand), 62(9):34-8.
71. Motovali-Bashi M, Rezaei H, Dehghanian F, et al (2014). Association between XPD (Lys751G1n) Polymorphism and Lung Cancer Risk: A Population-Based Study in Iran. Cell J, 16(3): 309-14.
72. Rikhtegar S, Hesampour A (2018). Investiga-tion of KRAS and NRAS expression lev-els in lung cancer patients compared to normal patients. Yafte, 20(3): 19-27.
73. Ahmadi M, Moshtaghioun SM, Falahati A (2018). Association of the CHRNA3 rs1051730 single nucleotide polymor-phism with lung cancer risk in Iranian pa-tients. JSSU, 26(7): 599-606.
74. Chitsaz M, Hesampour A (2018). Investigat-ing the Expression of EGFR and FGFR4 Genes in Patients with Lung Cancer. JBUMS, 20(4): 17-23.
75. Amini F, Motovalli Bashi M, Hemmati S (2018). Study of egfr gene in relationship between polymorphism and mir-214 binding site in lung cancer. Pejouhesh dar Pezeshki (Research in Medicine), 41(4): 268-274.
76. Motovali-bashi M, Taghvaei S, Hemati S (2012). The association between the C(-1562)t polymorphism of type IV colla-genase gene and reduced age of onset of lung cancer. Journal of Isfahan Medical School, 30(203): 1-9
77. Motovali-Bashi M, Bordbar M, Rezaei H (2012). Study of association between T/C single nucleotide polymorphism in CYP1A1 gene and cancer initiation and smoking status in lung cancer patients. Pejouhesh dar Pezeshki (Research in Medicine), 36(3): 151-6.
78. Motovali-Bashi M, Hojati Z (2013). Investi-gation of correlation between -765G/C polymorphism of cyclooxygenase 2 genes and lung cancer in Isfahan popula-tion. Pejouhesh dar Pezeshki (Research in Medi-cine), 37(1): 47-54.
79. Ghayyoumi M, Mansouri M (2015). Deter-mination of Serum level of Triose Phos-phate Isomerase in lung Cancer Patients. Armaghane Danesh, 19(11): 948-54.
80. Hamedi F, Tahmaseb M, A G (2016). Prog-nostic Importance of Polymorphisms in DNA-Repair Gene (XRCC1 Arg399Gln) in Patients with Lung Cancer in Fars Province, Iran. Journal of Isfahan Medical School, 34(403): 1244-50.
81. Keshvary Ravan H, Kouhkan F, Sazgar H (2017). Single Nucleotide Polymorphisms of MMP2 Gene Promoter on the Risk of Development and Metastasis of lung Cancer. Armaghane Danesh, 22(1): 104-17.
82. Sazgar H (2017). Evaluation of correlation between -1562 C/T in promoter single nucleotide polymorphisms of MMP-9 gene and lung cancer initiationand metas-tasis risk. Pars of Jahrom University of Medical Sciences, 15(2): 9-16.
83. Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, et al (2015). The incidence and mortality of lung cancer and their re-lationship to development in Asia. Transl Lung Cancer Res, 4(6): 763-74.
84. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer inci-dence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19(8):1893-907.
85. Bogos K, Kiss Z, Gálffy G, et al (2019). Re-vising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemi-ology Review from Hungary. Front Oncol, 9:1051.
86. de Groot P, Munden RF (2012). Lung can-cer epidemiology, risk factors, and pre-vention. Radiol Clin North Am, 50(5): 863-76.
87. Jazieh AR, AlGhamdi M, AlGhanem S, et al (2018). Saudi lung cancer prevention and screening guidelines. Ann Thorac Med, 13(4):198-204.
| Files | ||
| Issue | Vol 51 No 2 (2022) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v51i2.8683 | |
| Keywords | ||
| Lung cancer Epidemiology Risk factor; Survival Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Salehiniya H, Bahadori M, Ghanizadeh G, Raei M. Epidemiological Study of Lung Cancer in Iran: A Systematic Review. Iran J Public Health. 2022;51(2):306-317.
